Hummingbird Bioscience is an innovative biotherapeutics company pioneering the discovery and development of new breakthrough precision antibody therapeutics for difficult-to-treat conditions

Leveraging its proprietary rational antibody discovery platform and deep experience in systems biology, Hummingbird Bioscience is able to accurately identify important disease targets and engineer antibodies to precisely hit these difficult targets. Hummingbird Bioscience has developed a pipeline of highly promising novel therapies, and has established collaborations with leading partners


  • Novel, integrative approaches to disease biology
    Recognition of the importance of both tumor evolution and evasion of immune response as a key “hallmark of cancer” has provided a wide new class of targets. Building on these insights, Hummingbird is developing a comprehensive framework to systematically address the barriers to an effective immune response in every patient.
  • Rational Antibody Discovery Platform
    A highly innovative systems immunology and computational structural biology approach that enables precise targeting of epitopes and mechanism of action
  • Data and model driven translational medicine and biomarker identification
    Mechanism driven -omics analysis informs selection of appropriate pre-clinical models, role of tumor heterogeneity and down-stream biomarker development 



Recent News


  • 5 December 2019 Hummingbird Bioscience raises $19 Million in Series B financing to support expansion of its discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics (Full Press Release)
  • 16 September 2019 Hummingbird Bioscience announces collaboration with Amgen to co-discover novel therapeutics using Hummingbird’s Rational Antibody Discovery Platform (Full Press Release)

  • 8 August 2019 Cancer Research UK and Hummingbird Bioscience join forces to advance novel antibody drug into clinical trials (Full Press Release)
  • 25 February 2019 Hummingbird Bioscience awarded $13.1 Million grant by the Cancer Prevention and Research Institute of Texas (CPRIT) (Full Press Release)

  • 18 February 2019 Hummingbird Bioscience announces Nobel Laureate Dr. James Allison and Dr. Padmanee Sharma join its Scientific Advisory Board (Full Press Release)

  • 9 November 2018 Hummingbird Bioscience to present data on HMBD-001-10D1 at the EORTC-NCI-AACR's 30th Annual Meeting (Full Press Release)
  • 5 November 2018 Hummingbird Bioscience to present data on HMBD-002-V4 at the Society for Immunotherapy of Cancer (SITC)'s 33rd Annual Meeting (Full Press Release)